GLS and central nervous system cancer: This study suggests that Chr-A markedly reduces the expression levels of GLS, GDH1, HK2 and G6PD in U87 and U251 glioma cells, which support the significant metabolic pathways identified through AFADESI-MSI, suggesting that these key enzymes might be potential targets for Chr-A (Figure 5C–F).